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Safety and perception: what are the greatest enemies of HPV vaccination programmes? 
 
Abstract 
Vaccines stimulate a person’s immune system to produce an adequate reaction against a specific 
infectious agent; i.e. the person is protected from that disease without having to get it first. As 
vaccines are administrated to healthy subjects, they are held to the highest standards of safety. 
Regarding human papillomavirus (HPV) vaccines, at present three prophylactic vaccines are 
licensed (bivalent HPV 16/18, quadrivalent HPV 6/11/16/18 and the nonovalent HPV 
6/11/16/18/31/33/45/52/58 vaccine). Pre- and post-licensure studies (i.e. not yet for nonovalent 
HPV vaccine) confirm that HPV vaccines are generally safe and well-tolerated, site injections 
symptoms are the most common adverse events (AEs) reported, and pain is the most frequently 
referred local symptom. Serious AEs are rare and not associated with severe sequelae, at least no 
vaccine-related deaths have occurred. Despite these scientific evidences, it is still difficult to 
explain to the population the importance of a good vaccination programme. There are many 
determinants for HPV vaccines hesitancy which represent a barrier that must be overcome in order 
to increase vaccine coverage, including psychological reactions, religious or cultural aspects, and 
fear of possible AEs (demyelinating diseases, Complex Regional Pain Syndrome - CRPS, or 
Postural Orthostatic Tachycardia Syndrome - POTS). A weak communication strategy which 
frequently suffers due to spread of unverified news by media and websites may lead to the failure of 
a vaccination programme. Such a situation happened in Japan (2013), due to which a great number 
of women remain vulnerable to HPV-related cancers. In order to resolve the issues around HPV 
vaccines acceptance, it is necessary to use good communication strategies. Multicomponent and 
dialogue-based interventions seem to be the most effective, especially if an adequate language is 
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Introduction   
Vaccines stimulate a person’s immune system to produce an adequate reaction against a specific 
infectious agent, protecting the person from the disease without having to get it first [1]. Unlike 
most medicinal products that treat or cure diseases, vaccines prevent them [2]. Vaccines act at both 
individual and population levels (herd immunity) and can modify the immune status and the 
epidemiology of an infectious disease (ID) also reducing the circulation of an infectious agent.  
As the aim of vaccines is preventive and not therapeutic, they are administrated to a large number of 
healthy subjects (usually children or adolescents); thus, even the smallest adverse event (AE) is 
perceived as not tolerable. For this reason, vaccines are held to the highest standards of safety. The 
potential for any risk is considered less acceptable in the case of vaccines than in that of disease 
treatment. It will be an increasing challenge to spread the benefits of vaccination in the apparent 
absence of the disease but with the possible presence - even if mild - of adverse events following 
immunization (AEFIs) [3].  
Safety - a major issue for any vaccine - is assessed at every step of vaccine development (preclinical 
and clinical studies) and after licensure; as a matter of fact, health authorities require an on-going 
commitment for post-licensure analysis of safety [4]. The Global Advisory Committee on Vaccine 
Safety (GACVS) - an independent scientific advisory board - provides the World Health 
Organization (WHO) with strict advice on vaccine safety issues of global importance [5]. 
Broad community confidence in the vaccines’ safety is critical for generating maximum public 
health benefit. One reason for this is herd immunity effect, which is achieved when the vaccine 
coverage in the population is sufficient to prevent the circulation of the infectious agent among 
those who remain susceptible. This is only possible if the public has confidence in the safety of a 
vaccine. The study of AEs of vaccine is not only an effort to provide individuals with a basis for 
deciding whether to vaccinate, but also an effort to improve the safety and effectiveness of vaccines 




The aim of this paper is giving an overview about the main determinants, which influence in a 
negative way, an immunisation programme, focusing especially on HPV vaccination, trying also to 
provide some advices in communication strategies for overcoming this issue.  
 
Vaccine Surveillance 
Vaccine safety is continuously monitored to identify and evaluate potentially occurring rare and/or 
serious AEs that are temporally linked to vaccination (sudden deaths, immune-mediated disorders, 
narcolepsy). The Vaccine Adverse Event Surveillance and Communication (VAESCO) is an 
European research network, funded by European Centre for Disease Prevention and Control 
(ECDC), which collects data on AEFI in Europe and compare them in order to provide high quality 
vaccine information [7]. The Vaccine Adverse Reporting System (VAERS) – sponsored by Centers 
for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) - and 
New Vaccine Surveillance Network Extended System (NVSN-ES) cooperate with the aim of 
gathering information about AEs, that may occur after the administration of vaccine licensed for use 
(VAERS,) and to better evaluate the impact of new vaccines or new vaccine’s policies (NVSN-ES) 
in the US area [8]. When needed, studies are planned to assess safety signals and distinguish 
between possible causes and likely coincidence [9, 10, 11].  
The passive vaccine surveillance is carried out with the voluntary reporting of AEs from healthcare 
providers, vaccine-takers, and others (parents, relatives, friends, etc.) [12] and can be designed to 
recognize new or rare AEs and changes in rates of previously reported AEs [12, 13 ]. Nevertheless, 
the variability of reporting, reporter bias, and potential underreporting are limitations that hinder the 
defining of a causality relationship [12, 14]. Instead, active vaccine surveillance is a systematic 
procedure for identifying clinically significant events that occur within a defined period and/or 
population; this can assess whether a specific AE is significantly associated with the immunization 
[15, 16].  
 
 
Vaccines are also associated with the theoretical risk of adverse immunological responses that may 
lead to immune-mediated disorders: this could be due to homology between vaccine antigen and a 
human protein, or non-specific immune enhancement properties of the vaccine adjuvant [4, 17, 18]. 
Surveillance is an essential tool to generate signals and hypotheses but cannot be used to prove 
them. A well-designed and controlled study allows researchers to test hypotheses and to assess 
whether there is evidence and what is the size of the effect. The main methods used in this 
evaluation - case-control studies, cohort studies, and case-only methods - require the 
implementation of statistical calculation to support quantitative signal detection through 




     
                                               
                                                           
     
 
The PRR measures a reporting relationship between a medicinal product (e.g. vaccines) and an AE, 
based on the relative increase in proportion of individual cases related to an AE [19]. In essence, 
PRR is the proportion of all cases related to an AE reported after the administration of a vaccine, on 
the total number of cases of the same AE reported for all vaccines. If the expected value is one, AE 
is reported after the vaccine at the same probability as after all vaccines. If the value is greater than 
one, the AE is reported with more likelihood after that vaccine compared to what is reported after 
the totality of the vaccines [20]. 
 
Vaccine Hesitancy: main determinant categories 
According to WHO and the Strategic Advisory Working Group (SAGE WG), Vaccine Hesitancy is 
“the delay in acceptance or refusal of vaccines despite availability of vaccination services” [21]. It 
is a complex issue that is context-specific, varies across times, places, and vaccines, and includes 
complacency, convenience, and confidence as the main determinant factors [21]. Among the global 
 
 
population, during the last few years, it is raised a significant sense of criticism and alarmism to 
vaccines: immunization programmes have successfully reduced the incidence of vaccine-
preventable diseases, leading to an increasing proportion of healthcare providers and parents with 
little or no personal experience about vaccine-preventable diseases. For their risk-benefit analysis, 
they have to rely on the historical descriptions of such vaccine-preventable diseases. The public is 
no longer used to seeing these diseases and may think that vaccines are no longer needed. 
Moreover, the AEs of vaccines become more evident due to the absence of the disease the vaccine 
is supposed to prevent [17]. Therefore, on one side there is the perception that an ID may not be 
harmful. On the other side, there is the perception that a vaccine could be dangerous for any 
possible AE. People are also aware that vaccines are usually accompanied by some degree of 
personal distress and pain, and the apprehension is generally associated with each immunization. In 
addition, parents searching for information about vaccines on the Internet are likely to encounter 
websites that encourage vaccine refusal or emphasize the risks of vaccines. Likewise, the media 
may sensationalize vaccine safety issues or - in an effort to present “both sides” of this topic - fail to 
provide perspective. The combination of these factors may have an influence on parental beliefs 
about immunization [17]. A national telephone survey in United States found that, although the 
majority of parents support immunizations, 20–25% have misconceptions that may gradually erode 
their confidence in vaccines [23]. 
 
HPV vaccines 
Currently, three prophylactic HPV vaccines are licensed: the bivalent HPV16/18 virus-like particle 
(VLP) vaccine, the quadrivalent HPV 6/11/16/18 VLP vaccine, and the latest nonovalent HPV 
6/11/16/18/31/33/45/52/58 VLP vaccine, which offers a broader coverage than the bivalent and 
quadrivalent vaccines [24]. The nonovalent HPV vaccine should provide protection against HPV 
types representing 90% of cervical cancer cases and 90% of genital wart cases, using the average 
of HPV-type prevalence [25]. They are highly immunogenic and protect mostly against the HPV 
 
 
types included in the vaccines, with little cross-protection against non-vaccine HPV types [26, 27, 
28, 29, 30]. All the vaccines are administrated in males and females from the age of nine years; 
boys and girls aged 9–14 (bivalent and nonovalent vaccines) or 9–13 (quadrivalent vaccine) should 
follow a two-dose schedule, while for people aged more than 14 years, the vaccine is generally 
given according to a three-dose regimen [31, 32, 33]. 
Though the new nonovalent HPV vaccine has five additional antigen types and a double 
quantitative of adjuvant (500 µg of amorphous aluminum hydroxyphosphate sulfate) compared to 
the quadrivalent vaccine [34], a combined analysis of seven phase-III clinical trials on nonovalent 
HPV vaccine confirms a similarity between the safety profile of nonovalent HPV vaccine and that 
of quadrivalent HPV vaccine [35]. Pre- and post- licensure studies (not yet for nonovalent HPV 
vaccine) confirm that all the HPV vaccines are generally safe and well-tolerated, site injections 
symptoms are the most common AEs reported, and pain is the most frequently referred local 
symptom. Serious AEs are rare and not associated with severe sequelae, at least no vaccine-related 
deaths have occurred [31, 32, 33, 36]. Despite these reassuring findings on vaccine safety, anxiety 
among parents and girls regarding serious AE and unknown side-effects is still a barrier to the 
acceptance of vaccination, which may lead to the failure of a vaccine programme [37]. 
 
Main “enemies” of HPV vaccination programmes 
Despite scientific evidence, it is still difficult to explain to the population the importance of a strong 
vaccination programme: many determinants for HPV vaccines hesitancy represent a barrier that 
must be overcome in order to increase vaccine coverage. Public concerns and rumors about AEs, 
low confidence in safety findings by health authorities, cultural, religious, or social aspects, and 
wrong information collected from websites are some of the main factors that may cause an 
insufficient involvement in an HPV vaccination programme. These factors can be considered part of 
the three macro categories described in the model of determinants of vaccine hesitancy proposed by 
 
 
SAGE WG: contextual influences, vaccine or vaccination specific issues and individual or group 
influences [38, 39]. 
Evidence suggests that some events are often psychological reactions that can spread quickly, 
especially among the young community, such as schools, where girls are vaccinated in groups and 
may observe the reactions of one another. Further, there are short video clips on YouTube in which -
people describe their sense of anxiety towards the vaccination [40]. 
HPV vaccine programmes may also clash with some religious or cultural aspects of the society. In 
fact, as the aim of the vaccines is to prevent sexual transmission of HPV, this could evoke moral 
judgment in regard to sexual behavior [40], especially for those ethnic groups in which sexuality is 
still considered a taboo and girls and young women do not receive adequate sexual education. In 
light of this, some healthcare providers prefer to focus on promoting HPV vaccine as a means to 
prevent cancer rather than a sexual transmitted infection (STI), making it more acceptable [41, 42]. 
Further, parents are worried about the possibility that their young daughters may become sexually 
active too early or display promiscuous behavior [43, 44, 45, 46, 47, 48]; however, as many studies 
highlight, this hypothetic effect is not realized. A cohort study conducted between July 2006 and 
December 2007, with nearly 1,400 girls age 11–12 years, has demonstrated that HPV vaccination in 
the recommended ages for young girls is not associated with clinical markers of increased sexual 
activity or related outcomes such as sexually transmitted diseases or pregnancy [49]. 
Fear of possible AEs among the people has raised, for example, the idea that vaccination can lead to 
increase in multiple sclerosis, optic neuritis, transverse myelitis, acute disseminated 
encephalomyelitis, and neuromyelitis optica [50, 51, 52]. A cohort study (2015) of Danish and 
Swedish girls and women aged 10–44 years evaluated almost 4 million women and found no risk 
for the development of multiple sclerosis or other central nervous system-demyelinating diseases. 
Hence, these results do not support the alarmism about a causal relationship between quadrivalent 
HPV vaccination and demyelinating diseases [53]. 
 
 
The apprehension about the possibility of developing Complex Regional Pain Syndrome (CRPS) or 
Postural Orthostatic Tachycardia Syndrome (POTS) following HPV vaccination has increased 
among the population, mostly due to media reports alleging AEs and negative information, 
available internationally on the Internet. Both are disorders of unclear and heterogeneous etiology 
and their epidemiology is not well characterized. CRPS is a chronic pain syndrome affecting limbs, 
while POTS involves an abnormal increase in the heart rate while a person is standing up [54], 
together with symptoms such as dizziness, fainting, and weakness, or headache, body aches, nausea, 
and fatigue. In January 2016, the European Medicine Agency (EMA) published a review 
confirming that HPV vaccines do not cause CRPS or POTS. Despite the difficulties in diagnosing 
or fully characterizing CRPS and POTS, the scientific findings of the EMA’s review suggest that 
there is no causal link between the three licensed vaccines (bivalent, quadrivalent, and nonovalent 
HPV vaccines) and the development of CRPS or POTS [55]. 
 
The importance of a good communication strategy to overcome HPV-vaccination hesitancy 
As previously discussed, many factors have influenced people’s opinions and their choice in regard 
to taking or not taking a vaccination. The dissemination of the importance of an HPV vaccine 
programme needs good communication strategies that may vary according to political or cultural 
structures. The role of the media should also be taken into account, especially for the information 
about AEs, because vague information could seriously affect a good vaccination programme. The 
incident in Japan in 2013 is an example of a weak communication approach, which also suffered of 
the rapid spread of unverified news by media. These information found breeding ground mostly in 
that part of Japanese population that had previously lost the confidence in the medical profession 
and the pharmaceutical industry, especially due to two past vaccine controversies [56]. 
In Japan, the HPV vaccine (Cervarix ®) was licensed in October 2009. In April 2013, it was added 
to the Japanese government’s list of recommended vaccinations. Between March 2010 and March 
2013, before the addition of the HPV vaccine to the National Immunization Programme, local 
 
 
media channels reported some events occurring after HPV vaccination: more than 50 cases of girls 
complaining of CRPS, nine cases of chronic pain, about 100 cases of absenteeism from school, and 
videos of girls suffering from walking problems and seizure were shown during a press conference 
by a “victim group” [57]. Due to these highly publicized cases of alleged AEs following 
immunization, even though there was no proved causal relationship between the reported facts and 
the vaccination, the Japanese Ministry of Health, Labor and Welfare (MHLW) suspended the 
proactive recommendation of HPV vaccination in June 2013, continuing to provide it for free to 
girls aged 12–16 years. This decision of the MHLW stoked the public doubts about the vaccine’s 
safety [57]. Another fact that contributed to the increase in the sense of uncertainty and distrust in 
the population was the claim for a compensation from the leader of the Nationwide Cervical Cancer 
Victim Liaison Committee, whose daughter developed CRPS and lost the ability to walk after 
vaccination with Cervarix ® [58]. The national government and the local government of Suginami 
(where the girl’s family lived) refused to pay, because the HPV vaccine was not yet in the National 
Immunization Programme when the girl received it. But in April 2013, under strong pressure by the 
media, the Suginami government provided the compensation [59]. 
The decision of MHLW to withdraw its recommendation of HPV vaccine, along with the Japanese 
media’s often negative view of the vaccine, reinforced the confusion and uncertainty about the 
vaccination. Despite the efforts by the MHLW to add a Question and Answer (Q&A) page on its 
website about the HPV vaccine, including a section on the safety [60] and the release of a guidance 
for healthcare professionals [61], the sense of distrust for the vaccination increased among the 
people. The ambiguity in the decision to suspend the “active recommendation” of HPV vaccine but 
not the “administration” further allowed for misinterpretation, which spread quickly and globally on 
international mainstream media and on social networks (such as Facebook or Twitter). The 
suspension of the recommendation of HPV vaccine has obviously been widely applauded by the 
anti-vaccination groups, but not by the global scientific community [57]. Though the reassuring 
results from review of clinical data have led to the conclusion that symptoms were not vaccine-
 
 
related, it has been very difficult to reach a new consensus in order to resume HPV vaccination. 
Therefore, it has been evaluated that young Japanese women are being left vulnerable to HPV-
related cancers that could be prevented [54]. 
Vaccine hesitancy is a complex issue and a single strategy cannot resolve it; therefore, 
multicomponent and dialogue-based interventions are the most effective plans and these should be 
directed at unvaccinated or under-vaccinated populations or at specific target groups (as local 
community or health care workers) [62]. Selecting a population has been shown to be useful, 
pointing out the importance of combining the intervention to the reason of the low acceptance [63]. 
Multiple studies show that in European countries, healthcare providers are identified as the most 
important and reliable source of information on protection from vaccine-preventable diseases [64, 
65, 66], playing an important role mostly for parents who often have many questions or doubts 
about vaccines. During the last few years, some health organizations like European Centre Disease 
Prevention and Control (ECDC) and WHO have published guidelines in order to provide useful 
advice, based on scientific evidences, to all healthcare personnel. Some documents refer to 
immunization in wider terms, like “Let’s talk about protection enhancing childhood vaccination 
uptake communication guide for healthcare providers” [67], while others are more specific about 
HPV vaccine, like “HPV Vaccine Communication - Special Consideration for a unique vaccine, 
2016 update” [68]. Health authorities should invest more in training health care workers or should 
prevent vaccine hesitant behaviors within health personnel in order to address the vaccine hesitancy 
concern among patients or parents [39]. 
More and more frequently, people are searching for news about health by themselves; therefore, it 
is necessary to provide scientific information, written in an efficacious and adequate language, to all 
the citizens. The main channel where people look for information is the Internet, but a 
communication strategy based only on online data would not be very productive for people who are 
not so familiar with web-surfing or the use of social media. Further, some evidences suggest that 
social media can also be exploited if not managed well [62]. In fact, regarding the Japanese case, 
 
 
the ambiguous and possibly threatening setting arisen from  AEs following HPV vaccination -
whether deemed causal or not - accelerated an information-seeking process, which in turn 
reinforced the pre-existing beliefs and concerns [57]. 
WHO, Center for Disease Control and Prevention (CDC), and national health institutions 
periodically publish informative material about HPV vaccination: dedicated web pages available to 
the users [69, 70] or booklets describe the HPV infection, its set of problems, and how the efficacy 
(strongly confirmed by the clinical trials) of the HPV vaccines could prevent both the infection and 
the related cancers. As the target of the used communication strategies is variable (parents, girls, 
boys, or young adults), the language has to be the most suitable for the specific audience. Parents 
should receive reassuring words from their pediatrician, teenagers should understand the value of 
the vaccination through simple examples that may use also a graphic approach. Regarding young 
adults (as men that may think the HPV infection/vaccine is only a female problem), the language 
used in the information collected from papers, or websites or reported by physicians should take 
into account the schooling level. This would guarantee the spread of important information about 
the person’s health, overcoming possible cultural, social, or religious obstacles and avoiding 
communication inequalities or disparities in vaccination service access. Video-spot, written 
testimonies, or short video-clips [71] of female survivors of cervical cancer who have decided to 
share the own experience, have a positive impact on the public and promote the importance of 
vaccination. Asthe findings released by SAGE WG suggest [39], a multicomponent dialogue-based 
strategy to overcome the HPV vaccine hesitancy should include the engagement of religious or 
influential leaders in community and the communication training for health care workers as 
example of possible dialogue-based parts with the target population. Further, the improvement of 
the access to the vaccination service, the low costs of the immunization (e.g. for women or men not 
included in national plan of immunization), social and mass media interventions could increase the 






Since it was first licensed in 2006, more than 200 million doses of HPV vaccines have been 
distributed worldwide [54]. WHO recommends that the introduction of HPV vaccines into national 
immunization programmes be made into a public health priority, to ensure prevention of cervical 
cancer and/or other related diseases. Vaccine implementation is programmatically feasible and 
financially sustainable. Further, the cost-effectiveness of vaccination strategies in the country or 
region should be considered [72]. The GACVS has analytically investigated safety concerns about 
HPV vaccines and has released several reports on this topic [73]: to date, GACVS has not found 
any safety concern that would modify its recommendations for the use of the three licensed 
vaccines [46].  
Distrust in vaccination programmes is an old issue. It was born in the mid-1980s, and in these last 
few years the dynamic and challenging period of indecision with regard to accepting a vaccination 
(vaccine hesitancy) has increased. Many factors (e. g. cultural, social, or religious aspects, 
spreading of unverified information by media or social media) may influence people’s opinion 
about vaccines [38,39].  Concerning the HPV vaccination, for example  many people are worried 
about suffering a possible AE after the immunization [50, 51, 52, 55];  or are trouble about moral 
judgements on their sexual activity and behavior due to the aim of the vaccine (to prevent sexual 
transmitted infections) [40].  . In order to resolve all the issues around HPV vaccine acceptance, it is 
necessary to include good communication strategies: multicomponent and dialogue-based 
interventions seem to be the most effective [38,39,62,63] .  
The benefits of HPV vaccines continue to outweigh the known side-effects. However, the safety of 
these vaccines will continue to be monitored, taking into account any newly discovered evidence of 
any AE [55]. The constant pharmacovigilance activity ensure that concerns related to the HPV 
vaccines administration can be addressed with the best possible evidence. Enhanced spontaneous 
 
 
reporting of AEFI should be ensured to guarantee that those who could benefit the most from the 
intervention are vaccinated with a medicinal product of high and adequate safety standard [54]. 
Regarding the importance of the new nonovalent HPV vaccine, it will be important to carry out 
effective communication strategies using not only traditional tools, like guidelines or booklets, but 
also digital interface like social media or mobile applications (“apps”). Following the concept of 
“Pneumo Rischio” [74, 75], it could be interesting to develop a user-friendly app, which could 
increase people’s knowledge and awareness about HPV infections and vaccines.  The use of the 
adequate language - customized according to the vaccination programme target - should ensure the 
spread of the efficacy, safety, and the added value of the nonovalent HPV vaccine. 
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Safety and perception: what are the greatest enemies of HPV vaccination programmes? 
 
Abstract 
Vaccines stimulate a person’s immune system to produce an adequate reaction against a specific 
infectious agent; i.e. the person is protected from that disease without having to get it first. As 
vaccines are administrated to healthy subjects, they are held to the highest standards of safety. 
Regarding human papillomavirus (HPV) vaccines, at present three prophylactic vaccines are 
licensed (bivalent HPV 16/18, quadrivalent HPV 6/11/16/18 and the nonovalent HPV 
6/11/16/18/31/33/45/52/58 vaccine). Pre- and post-licensure studies (i.e. not yet for nonovalent 
HPV vaccine) confirm that HPV vaccines are generally safe and well-tolerated, site injections 
symptoms are the most common adverse events (AEs) reported, and pain is the most frequently 
referred local symptom. Serious AEs are rare and not associated with severe sequelae, at least no 
vaccine-related deaths have occurred. Despite these scientific evidences, it is still difficult to 
explain to the population the importance of a good vaccination programme. There are many 
determinants for HPV vaccines hesitancy which represent a barrier that must be overcome in order 
to increase vaccine coverage, including psychological reactions, religious or cultural aspects, and 
fear of possible AEs (demyelinating diseases, Complex Regional Pain Syndrome - CRPS, or 
Postural Orthostatic Tachycardia Syndrome - POTS). A weak communication strategy which 
frequently suffers due to spread of unverified news by media and websites may lead to the failure of 
a vaccination programme. Such a situation happened in Japan (2013), due to which a great number 
of women remain vulnerable to HPV-related cancers. In order to resolve the issues around HPV 
vaccines acceptance, it is necessary to use good communication strategies. Multicomponent and 
dialogue-based interventions seem to be the most effective, especially if an adequate language is 
used, customized according to the vaccination programme target. 
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